AFXD Stock Overview
Operates as a medical technology company in Germany, rest of Europe, North America, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Carl Zeiss Meditec AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €57.98 |
| 52 Week High | €116.40 |
| 52 Week Low | €56.45 |
| Beta | 1.04 |
| 11 Month Change | -9.63% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -67.83% |
| 5 Year Change | -45.67% |
| Change since IPO | 176.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| AFXD | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | 7.7% | -0.4% |
| 1Y | n/a | -2.1% | 5.6% |
Return vs Industry: Insufficient data to determine how AFXD performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how AFXD performed against the UK Market.
Price Volatility
| AFXD volatility | |
|---|---|
| AFXD Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: AFXD's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine AFXD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1846 | 4,950 | Markus Weber | www.zeiss.com/meditec-ag/de/investor-relations.html?vaURL=www.zeiss.de/meditec-ag/ir |
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders.
Carl Zeiss Meditec AG Fundamentals Summary
| AFXD fundamental statistics | |
|---|---|
| Market cap | €5.23b |
| Earnings (TTM) | €203.20m |
| Revenue (TTM) | €2.07b |
25.7x
P/E Ratio2.5x
P/S RatioIs AFXD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AFXD income statement (TTM) | |
|---|---|
| Revenue | €2.07b |
| Cost of Revenue | €927.44m |
| Gross Profit | €1.14b |
| Other Expenses | €935.57m |
| Earnings | €203.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Dec 11, 2024
| Earnings per share (EPS) | 2.27 |
| Gross Margin | 55.11% |
| Net Profit Margin | 9.83% |
| Debt/Equity Ratio | 6.7% |
How did AFXD perform over the long term?
See historical performance and comparison